About the new and improved Hot Tort Report
Being industry experts, we pride ourselves on keeping our finger on the pulse of all things Multi District Litigation. This predominantly consists of providing our subscribers with competitive insights into where the money is being spent in hopes of informing your blueprint for advertising strategies. These cases can be highly lucrative, but are difficult to acquire, requiring significant investment and patience to secure high-value cases.
We’ve been working hard on an algorithm to deliver more than just monthly TV spends and are proud to announce that we are ready to unveil our HTR 2.0.
This new list offers an overview of dollars spent across TV, Meta, PPC, and more, assigning a score to each tort based on what we, as leaders in the law firm advertising space, are witnessing across these various platforms.
The Hot Tort Report:
October 2026
The Hottest in Mass Tort Spending: September 2026
Social Media Addiction
Featured Tort
Subscribe to the Hot Tort Report
What’s the Tort News?
Published: October, 2026. Advertising spend from multiple sources for a recent 30-day period.
If you have any questions, please contact us at national@whitehardt.com
#1 Social Media Addiction
Social Media Addiction torts take the #1 spot for October, climbing from fourth place last month. Meta leads the channel mix with a perfect 5.0, accompanied by meaningful activity across WHii, TV and PPC.
The federal litigation remained active throughout September, with additional cases continuing to enter MDL 3047. This is an indication that the litigation is still expanding rather than simply working through previously filed claims. A new conditional transfer order was filed September 8 as cases continued to be centralized before Judge Yvonne Gonzalez Rogers in the Northern District of California. The MDL consolidates personal injury claims concerning alleged harms to young people from social media platforms.
That ongoing case growth coincides with a major increase in advertiser interest. With a 5.0 Meta score and spending measured across every channel, Social Media Addiction had the strongest overall advertising profile in September and moved from #4 to #1.
For metrics such as CPA, CPL, and common criteria, please contact us.
#2 Diabetes Meds for Weight Loss
After holding the top spot last month, the Diabetes Meds for Weight Loss mass tort slips to #2. The primary driver was a two-point decline in PPC. A 0.5-point increase in TV wasn’t enough to make up the difference, although WHii and Meta activity remained strong.
The pullback comes at a consequential point in the federal GLP-1 litigation. From September 14–18, Judge Karen Spencer Marston held a Rule 702 evidentiary hearing addressing scientific evidence underlying gastrointestinal injury claims in MDL 3094. The court’s eventual rulings on expert testimony could help determine which alleged injuries and causation theories can proceed, making this an important stage for firms evaluating the litigation and future case acquisition.
The MDL involves widely used medications including Ozempic®, Wegovy®, Rybelsus®, Trulicity®, and Mounjaro®, with plaintiffs alleging gastrointestinal injuries and manufacturers disputing those allegations. Advertiser interest remains high enough to keep the tort at #2, and firms are investing while important questions about the viability of the underlying claims remain before the court.
CPA: $91 – $1,056
CPL: $68 – $792
Common Criteria: Took a prescription diabetes drug for weight loss (e.g. Ozempic®, Mounjaro®), discontinued use of the drug, and experienced one or more gastrointestinal disorders at least 30 days after your first dose.
#3 Roblox Child Abuse
Roblox Child Abuse litigation continues its steady climb, moving from #5 last month into the top 3. Increased PPC activity during September supplied the additional boost needed to get it there, joining an already strong 5.0 Meta score.
The advertising increase comes as the relatively young federal litigation continues developing. The Judicial Panel on Multidistrict Litigation centralized Roblox child exploitation cases in the Central District of California earlier this year, creating a single proceeding for qualifying federal claims and establishing procedures for new plaintiffs to file directly into the MDL.
September also brought a potentially important procedural development. On September 3, the Ninth Circuit affirmed the denial of Roblox’s attempt to compel one plaintiff into arbitration, allowing that case to remain in court. The ruling was based on Roblox having waived its arbitration right through its conduct in that particular case, so it doesn’t eliminate arbitration as an issue across all Roblox claims. Still, when the plaintiffs’ ability to pursue a claim can deeply affect its size and trajectory, the decision is worth watching.
With PPC activity increasing as the federal litigation develops, Roblox Child Abuse moves two positions higher and becomes one of September’s biggest risers.
For metrics such as CPA, CPL, and common criteria, please contact us.
#4 9/11 Claims
The mass tort for 9/11 Claims takes the #4 position, with Meta at 5.0 and another 2.4 points coming from TV. September 11th’s 25th anniversary naturally brought renewed public attention, but the continuing claims market extends far beyond the anniversary itself.
In a message marking the anniversary, Victim Compensation Fund Special Master Allison Turkel reported that the VCF continues to receive more than 800 new claims each month. She also noted that deaths from 9/11-related health conditions have now surpassed the number of people killed on the day of the attacks.
That distinction is important for understanding the continuing advertising market. These aren’t simply claims tied to an event that occurred 25 years ago; the VCF continues processing new claims involving 9/11-related health conditions today. With especially strong Meta activity and a substantial TV presence during the anniversary month, 9/11 Claims move into the top 5.
For metrics such as CPA, CPL, and common criteria, please contact us.
#5 Birth Injury
Increases in both WHii and TV activity were enough to overcome a one-point decline in PPC, taking this tort from #7 to #5.
Unlike many categories in the Hot Tort Report, birth injury torts aren’t one centralized product-liability mass tort with a single federal MDL docket. Cases generally arise individually from the facts surrounding a particular pregnancy, delivery, provider and alleged injury. That makes it especially important not to treat individual verdicts or settlements as though they represent movement in one unified national litigation.
We’re keeping the focus this month on what the advertising data actually tells us. The broader increase across WHii and TV, combined with continued 5.0 Meta activity, was enough to move Birth Injury two positions higher and into the top 5.
For metrics such as CPA, CPL, and common criteria, please contact us.
#6 Hernia Mesh
Hernia Mesh falls to #6 this month. A modest increase in TV activity wasn’t enough to offset declines in WHii and Meta, although its 9.2 total keeps it close behind Birth Injury.
The decline comes as the massive Bard hernia mesh litigation moves deeper into the settlement stage. With much of that litigation now focused on resolving existing claims rather than building toward early bellwethers, the maturing docket provides useful context for the softer advertising activity we’re seeing this month. That doesn’t establish why individual advertisers pulled back, but it does distinguish Hernia Mesh from newer torts where firms are still aggressively building inventories.
TV remains a notable exception. At 2.9, it is Hernia Mesh’s strongest channel after Meta and actually increased in September, even as WHii and Meta declined enough to move the tort lower in the Top 10.
Common Criteria: Underwent hernia mesh surgery from 2000—present; suffered from one of the following: perforation, bowel obstruction, mesh erosion, mesh contraction, torn mesh, sepsis/infection, granuloma, adhesion, dehiscence that resulted in a removal/repair, scheduled or future.
For metrics such as CPA and CPL, please contact us.
#7 Birth Control Injections
Birth Control Injections lands at #7 following considerable movement between channels. WHii declined by 0.5 points and TV fell 1.1 points to zero, while PPC gained a full point.
September brought concrete movement in the federal Depo-Provera litigation. On September 4, the Northern District of Florida entered three case management orders appointing a Supplemental Compensation Fund Allocation Master, Qualified Settlement Fund Administrator, and Lien Resolution Master. Those appointments followed earlier orders addressing settlement administration and ongoing litigation.
This month’s advertising was concentrated in digital channels, with Meta at 5.0 and PPC gaining ground while measurable TV activity disappeared.
CPA: $5,169
CPL: $3,050
For common criteria, please contact us.
#8 Rideshare Sexual Assault
Rideshare Sexual Assault takes the #8 spot this month, with September advertising heavily concentrated on Meta. Meta scored a 5.0, compared with no measurable TV activity and more modest WHii and PPC scores.
The advertising activity came as the federal Uber sexual assault litigation moved toward another bellwether trial. In September, the court continued resolving disputes specific to the upcoming bellwether and set a schedule requiring the presentation of trial evidence to conclude by October 23. That approaching trial provides relevant context for continued advertiser interest in the tort, although the data doesn’t establish that it caused September’s spending.
For now, the advertising picture is distinctly digital: Meta accounts for 5 of the tort’s 8 total points.
For metrics such as CPA, CPL, and common criteria, please contact us.
#9 Medical Scope
Unlike the large federal MDLs elsewhere on this list, there is no comparable centralized federal Medical Scope proceeding to use as a litigation benchmark. There is, however, ongoing regulatory activity involving some of the devices at issue. FDA records show an open recall involving the Olympus TJF-Q190V duodenovideoscope, which followed continued reports of infections and led to updates for the reprocessing materials.
FDA’s MAUDE database also continued receiving adverse-event information involving Olympus scopes in 2026. MAUDE reports are important safety-surveillance records, but they don’t, by themselves, establish that a device caused an injury.
Despite a one-point PPC increase and continued strong Meta activity, declines across WHii, TV and Meta push Medical Scope three positions lower and leave it narrowly above the bottom of the top 10.
For metrics such as CPA, CPL, and common criteria, please contact us.
#10 Takata Airbag Recall
The Takata Airbag Recall lawsuits round out the top 10 this month. WHii slipped by half a point, but TV remained at a 5.0 and continues to account for most of the tort’s score. Notably, Takata recorded no measurable Meta activity, making its channel mix unusually TV-heavy.
That TV activity is occurring around a recall that remains an active consumer-safety issue in 2026. For September, the channel concentration is the bigger story: a perfect 5.0 TV score was enough to keep Takata in the top 10 despite the WHii decline, modest PPC activity and no measurable Meta presence.
For metrics such as CPA, CPL, and common criteria, please contact us.
Mesothelioma
You may be noticing a tort missing from our new report. While Mesothelioma continues to dominate the competition when it comes to spend levels, Whitehardt finds that this tort is its own niche animal. These cases can be extremely fruitful, but hard to come by, requiring a high buy-in to get in the game and patience when landing that ringer of a case. We believe that Meso will remain a constant for some time, but in regards to many of the other drugs and devices we focus on in this monthly report, we’ve decided to move it to its own category. If you are interested in hearing the latest news on Meso or how Whitehardt may be currently seeking these cases, you can contact us here.
Whitehardt will continue to track meso spending from month to month, so if you are interested in ongoing meso spending, please reach out to us directly. Going forward, we will be excluding meso from these tort reports.